We are in an old fashion sell off. Have we reached blood in the street/panic bottom yet? It does not quite feel like that yet but we are so oversold we could have that bounce today. If not then we are likely looking for a Tuesday reversal as markets generally do not bottom on Fridays. […]
March 4th Biotech (and MLP) Update
So I think it was a week ago or so that I said that $140 was very likely and then these bounces made it perhaps a little less clear, yesterday made it clear. The question now is whether or not that level will hold. Everything is setting up for a bounce. We had a large […]
March 3rd Biotech (and Energy) Update
The market has been rough. Not in that we have seen a ton of downside but more in terms of the whiplash we have seen. One day looks like a breakdown and the next looks like a breakout. I do not see any clear trend right now and until the market signals by moving out […]
March 1 Biotech Update
A good start to the week on relatively little news. I thought the sector had a clear shot down to the $140 or so level on the XBI but it is possible that the intraday move on Friday marked the bottom. We need more than simply a good start to the week but need it […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
